Bortezomib: a new therapeutic option for POEMS syndrome

Authors:

Abstract
Objective: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. Methods: We present a 65‐year‐old man with POEMS syndrome who was successfully treated with bortezomib. Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near‐to‐complete remission was achieved. His symptoms of polyneuropathy improved dramatically. Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.

This publication has 10 references indexed in Scilit: